Document is current
Any future updates will be listed below
-
Authors
Cappellari, Manuel https://orcid.org/0000-0002-3534-3201
Nicolini, Ettore
Saia, Valentina
Pracucci, Giovanni
Guido, Ludovica
Casetta, Ilaria
Fainardi, Enrico
Bracco, Sandra
Tassi, Rossana
Laiso, Antonio
Nencini, Patrizia
Ruggiero, Maria
Longoni, Marco
Saletti, Andrea
De Vito, Alessandro
Cavasin, Nicola
Critelli, Adriana
Menozzi, Roberto
Pezzini, Alessandro
Bergui, Mauro
Bosco, Giovanni
Comai, Alessio
Franchini, Enrica
Bigliani, Claudia Rolla
Markushi, Tiziana Benzi
Lozupone, Emilio
D’Agostino, Sabino
Vallone, Stefano
Bigliardi, Guido
Boghi, Andrea
Naldi, Andrea
Gallesio, Ivan
Canessa, Alessandro
Besana, Michele
Giossi, Alessia
Simonetti, Luigi
Zini, Andrea
Da Ros, Valerio
Lacidogna, Giordano
Burdi, Nicola
Tinelli, Angelica
Vinci, Sergio Lucio
La Spina, Paolino
Plebani, Mauro
Valletta, Francesco
De Michele, Manuela
Ciacciarelli, Antonio
Romi, Andrea
Persico, Alessandra
Lazzarotti, Guido Andrea
Mignani, Gaia
Perri, Marco
De Santis, Federica
Sanna, Antioco
Coco, Elena
Galvano, Gianluca
Saracco, Eleonora
Alberti, Matteo
Invernizzi, Paolo
Allegritti, Massimiliano
Caproni, Stefano
Chiumarulo, Luigi
Petruzzellis, Marco
Carità, Giuseppe
Russo, Monia
Puglielli, Edoardo
Casalena, Alfonsina
Niaz, Ahmed
Mangiafico, Salvatore
Toni, Danilo
,
- License Information
-
More Information
Article History
Received: 17 November 2025
Accepted: 9 March 2026
First Online: 25 March 2026
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: None.
: MC: consultancy or advisory board fees or speaker’s honoraria from Boehringer Ingelheim, Pfizer/Bristol Meyer Squibb, and Daiichi Sankyo, and Astrazeneca. RS: consultancy or advisory board fees or speaker’s honoraria from Boehringer Ingelheim, AstraZeneca, Daiichi-Sankjo, ML: consultancy or advisory board fees or speaker’s honoraria from Boehringer Ingelheim, Daiichi-Sankyo; AZ: consulting and speaker fees from Angels Initiative, Boehringer-Ingelheim, Alexion, Daiichi Sankyo, Pfizer, and fees for Advisory Board from Bayer, Daiichi Sankyo, Astra Zeneca, and Boehringer-Ingelheim, all outside of the submitted work. All other authors report no conflicts of interest.
